DoD Awards $136.7 Million Contract to MilliporeSigma to Establish Domestic Production Capacity of Critical Material Used in COVID-19 Point-of-Care Tests

View Online IMMEDIATE RELEASE DoD Awards $136.7 Million Contract to MilliporeSigma to Establish Domestic Production Capacity of Critical Material Used in COVID-19 Point-of-Care Tests Dec. 29, 2021 On Dec. 29, 2021, the Department of Defense (DoD), on behalf of and in coordination with the U.S. Department of Health and Human Services, awarded a $136.7 million contract to MilliporeSigma to establish nitrocellulose membrane production capacity in the United States. Nitrocellulose membrane is a critical material used in manufacturing SARS-CoV-2 rapid point-of-care tests. This industrial base expansion effort will allow MilliporeSigma to establish a nitrocellulose manufacturing capability in its Sheboygan, Wisconsin facility to support more than 83.3 million tests per month for COVID-19 testing and future needs. The DoD's Defense Assisted Acquisition Cell (DA2) led this effort in coordination with the Department of the Air Force's Acquisition COVID-19 Task Force (DAF ACT). This effort was funded through the American Rescue Plan Act (ARPA) to support domestic industrial base expansion for critical medical resources.

ABOUT   NEWS   HELP CENTER   PRESS PRODUCTS

Unsubscribe | Contact Us

This email was sent to sajanram.shrestha@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Department of Defense 1400 Defense Pentagon Washington, DC 20301-1400